^
Association details:
| Biomarker: | EGFR exon 19 deletion |
|---|---|
| Cancer: | Non Small Cell Lung Cancer |
| Drug: | gefitinib (EGFR inhibitor) + Fruzaqla (fruquintinib) (VEGFR inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Fruquintinib with gefitinib as first-line therapy in patients carrying EGFR mutations with advanced non-small cell lung cancer: a single-arm, phase II study
Published date:
02/01/2021
Excerpt:
ORR was 73.5% (95% CI, 58.9–85.1) and DCR was 98.0% (95% CI, 89.2–100.0). Median PFS was 14.7 months for both groups; PFS was highest for patients with exon-19 deletion (16.5 months; 95% CI, 12.9-21.2)....Combined fruquintinib and gefitinib treatment showed an acceptable safety profile and promising efficacy in newly diagnosed NSCLC patients harboring EGFR-activating mutations.
DOI:
10.21037/tlcr-20-1028
Trial ID:
